Search research articles
Contact Us
Filters
Showing results (71-80 of 208) with videos related to
Page
of 21
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 25, 2011
Phase I pharmacokinetic and pharmacodynamic study of SJG-136, a novel DNA sequence selective minor groove cross-linking agent, in advanced solid tumors
Igor Puzanov, Wooin Lee, Alice P Chen, et al.
The Oncologist
|
September 10, 2008
Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib
Mario E Lacouture, Shenhong Wu, Caroline Robert, et al.
Journal for Immunotherapy of Cancer
|
February 28, 2017
Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy
Eileen Shiuan, Kathryn E Beckermann, Alpaslan Ozgun, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
July 11, 2025
Protected Time, Resources, and Expectations for Academic Oncology Clinical Research Physicians
David E Gerber, Nikhil I Khushalani, Ang Gao, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
February 25, 2009
Retrospective analysis of the safety and efficacy of interleukin-2 after prior VEGF-targeted therapy in patients with advanced renal cell carcinoma
Daniel C Cho, Igor Puzanov, Meredith M Regan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 17, 2019
Extended 5-Year Follow-up Results of a Phase Ib Study (BRIM7) of Vemurafenib and Cobimetinib in <i>BRAF</i>-Mutant Melanoma
Antoni Ribas, Adil Daud, Anna C Pavlick, et al.
JCO Oncology Practice
|
August 22, 2024
Under-Representation and Under-Reporting of Minoritized Racial and Ethnic Groups in Clinical Trials on Immune Checkpoint Inhibitors
Alfredo V Chua, Jennifer Delmerico, Haiyang Sheng, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 30, 2009
Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1
Anthony W Tolcher, John Sarantopoulos, Amita Patnaik, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 19, 2015
Long-term outcome in BRAF(V600E) melanoma patients treated with vemurafenib: Patterns of disease progression and clinical management of limited progression
Igor Puzanov, Ravi K Amaravadi, Grant A McArthur, et al.
Biorxiv : the Preprint Server for Biology
|
December 4, 2023
Developing folate-conjugated miR-34a therapeutic for prostate cancer treatment: Challenges and promises
Wen Jess Li, Yunfei Wang, Xiaozhuo Liu, et al.
Page
of 21
Search research articles
Search
Showing results (71-80 of 208) with videos related to
Sort By:
Page
of 21
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 25, 2011
Phase I pharmacokinetic and pharmacodynamic study of SJG-136, a novel DNA sequence selective minor groove cross-linking agent, in advanced solid tumors
Igor Puzanov, Wooin Lee, Alice P Chen, et al.
The Oncologist
|
September 10, 2008
Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib
Mario E Lacouture, Shenhong Wu, Caroline Robert, et al.
Journal for Immunotherapy of Cancer
|
February 28, 2017
Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy
Eileen Shiuan, Kathryn E Beckermann, Alpaslan Ozgun, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
July 11, 2025
Protected Time, Resources, and Expectations for Academic Oncology Clinical Research Physicians
David E Gerber, Nikhil I Khushalani, Ang Gao, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
February 25, 2009
Retrospective analysis of the safety and efficacy of interleukin-2 after prior VEGF-targeted therapy in patients with advanced renal cell carcinoma
Daniel C Cho, Igor Puzanov, Meredith M Regan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 17, 2019
Extended 5-Year Follow-up Results of a Phase Ib Study (BRIM7) of Vemurafenib and Cobimetinib in <i>BRAF</i>-Mutant Melanoma
Antoni Ribas, Adil Daud, Anna C Pavlick, et al.
JCO Oncology Practice
|
August 22, 2024
Under-Representation and Under-Reporting of Minoritized Racial and Ethnic Groups in Clinical Trials on Immune Checkpoint Inhibitors
Alfredo V Chua, Jennifer Delmerico, Haiyang Sheng, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 30, 2009
Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1
Anthony W Tolcher, John Sarantopoulos, Amita Patnaik, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 19, 2015
Long-term outcome in BRAF(V600E) melanoma patients treated with vemurafenib: Patterns of disease progression and clinical management of limited progression
Igor Puzanov, Ravi K Amaravadi, Grant A McArthur, et al.
Biorxiv : the Preprint Server for Biology
|
December 4, 2023
Developing folate-conjugated miR-34a therapeutic for prostate cancer treatment: Challenges and promises
Wen Jess Li, Yunfei Wang, Xiaozhuo Liu, et al.
Page
of 21